Application of Nanotechnology in Cancer Treatment

One-step preparation, characterization, and anticancer potential of ZnFe2O4/RGO nanocomposites

Zinc ferrite nanoparticles (ZnFe2O4 NPs) have attracted extensive attention for their diverse applications including sensing, waste-water treatment, and biomedicine. The novelty of the present work is the fabrication of ZnFe2O4/RGO NCs by using a one-step hydrothermal process to assess the influence of RGO doping on the physicochemical properties and anticancer efficacy of ZnFe2O4 NPs. X-ray diffraction (XRD), Scanning electron microscopy (SEM), Energy-dispersive X-ray(EDX), X-ray photoelectron spectroscopy (XPS), Fourier-transform infrared spectroscopy (FTIR), UV-vis spectroscopy, and Photoluminescence (PL) spectroscopy were employed to characterize prepared pure ZnFe2O4 NPs and ZnFe2O4/ RGO NCs. XRD results showed that the synthesized samples have high crystallinity. Furthermore, the average crystal sizes of ZnFe2O4 nanoparticles (NPs) and ZnFe2O4/RGO nanocomposites (NCs) were 51.08 nm and 54.36 nm, respectively. SEM images revealed that pure ZnFe2O4 NPs were spherical in shape with uniformly loaded on the surface of the RGO nanosheet. XPS and EDX analysis confirmed the elemental compositions of ZnFe2O4/RGO NCs. Elemental mapping of SEM shows that the elemental compositions (Zn, Fe, O, and C) were homogeneously distributed in ZnFe2O4/RGO NCs. The intensity of FT-IR spectra depicted that pure ZnFe2O4 NPs were successfully anchored into the RGO nanosheet. An optical study suggested that the band gap energy of ZnFe2O4/RGO NCs (1.61 eV) was lower than that of pure ZnFe2O4 NPs (1.96 eV). PL spectra indicated that the recombination rate of the ZnFe2O4/ RGO NCs was lower than ZnFe2O4 NPs. MTT assay was used to evaluate the anticancer performance of ZnFe2O4 /RGO NCs and pure ZnFe2O4NPs against human cancer cells. In vitro study indicates that ZnFe2O4 /RGO NCs have higher anticancer activity against human breast (MCF-7) and lung (A549) cancer cells as compared to pure form ZnFe2O4 NPs. This work suggests that RGO doping enhances the anticancer activity of ZnFe2O4NPs by tuning its optical behavior. This study warrants future research on potential therapeutic applications of these types of nanocomposites.

Chitosan Nanomedicine in Cancer Therapy: Targeted Delivery and Cellular Uptake

Nanomedicine has gained much attention for the management and treatment of cancers due to the distinctive physicochemical properties of the drug-loaded particles. Chitosan's cationic nature is attractive for the development of such particles for drug delivery, transfection, and controlled release. The particle properties can be improved by modification of the polymer or the particle themselves. The physicochemical properties of chitosan particles are analyzed in 126 recent studies, which allows to highlight their impact on passive and active targeted drug delivery, cellular uptake, and tumor growth inhibition (TGI). From 2012 to 2019, out of 40 in vivo studies, only 4 studies are found reporting a reduction in tumor size by using chitosan particles while all other studies reported tumor growth inhibition relative to controls. A total of 23 studies are analyzed for cellular uptake including 12 studies reporting cellular uptake mechanisms. Understanding and exploiting the processes involved in targeted delivery, endocytosis, and exocytosis by controlling the physicochemical properties of chitosan particles are important for the development of safe and efficient nanomedicine. It is concluded based on the recent literature available on chitosan particles that combination therapies can play a pivotal role in transformation of chitosan nanomedicine from bench to bedside.

In vitro Biological Tests as the First Tools To Validate Magnetic Nanotheranostics for Colorectal Cancer Models

Colorectal cancer (CRC) remains a leading cause of cancer death. Nanotechnology has focused on reaching more effective treatments. In this concern, magnetic nanoparticles (MNPs) have been studied for a wide range of biomedical applications related to CRC, such as diagnostic imaging, drug delivery and thermal therapy. However, limited research is currently found in the open literature that refers to nanosystems combining all these mentioned areas (theranostics). When developing nanosystems intended as theranostics applied to CRC, possible variations between patients must be considered. Therefore, multiple in vitro assays are required as guidance for future preclinical and clinical trials. The objective of this contribution is to evaluate the available and recent literature regarding the interactions of MNP and CRC models, aiming to critically analyze the information given by the commonly used assays and evaluate the data provided by each one with a view to implementing this novel technology in CRC diagnostics and therapy.

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225

Actinium-225 (²²⁵Ac) is receiving increased attention for its application in targeted radionuclide therapy, due to the short range of its emitted alpha particles in conjunction with their high linear energy transfer, which lead to the eradication of tumor cells while sparing neighboring healthy tissue. The objective of our study was the evaluation of a gold nanoparticle radiolabeled with ²²⁵Ac as an injectable radiopharmaceutical form of brachytherapy for local radiation treatment of cancer. Au@TADOTAGA was radiolabeled with ²²⁵Ac at pH 5.6 (30 min at 70 °C), and in vitro stability was evaluated. In vitro cytotoxicity was assessed in U-87 MG cancer cells, and in vivo biodistribution was performed by intravenous and intratumoral administration of [²²⁵Ac]²²⁵Ac-Au@TADOTAGA in U-87 MG tumor-bearing mice. A preliminary study to assess therapeutic efficacy of the intratumorally-injected radio-nanomedicine was performed over a period of 22 days, while the necrotic effect on tumors was evaluated by a histopathology study. We have shown that [²²⁵Ac]²²⁵Ac-Au@TADOTAGA resulted in the retardation of tumor growth after its intratumoral injection in U87MG tumor-bearing mice, even though very low activities were injected per mouse. This gold nanoparticle radiopharmaceutical could be applied as an unconventional brachytherapy in injectable form for local radiation treatment of cancer.